All fourteen rectal cancer patients in a small phase II study of dostarlimab, an anti-PD-1 monoclonal antibody, saw their cancer completely disappear—with no progression or recurrence at follow-up six to 25 months later. None of the patients required further chemotherapy, radiation, or surgery.
J. Leonard Lichtenfeld joined SpotitEarly, an Israel-based technology company transforming cancer screening by harnessing the power of artificial intelligence and dogs to detect cancer early, as chief medical officer.
